skip to Main Content



Alimera is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people in our aging populations.

IR Nav

Tear Sheet IR Contacts Subscribe to News Alerts RSS Feed

Company Profile

6120 Windward Parkway, Suite 290
Alpharetta, GA 30005

1 (844) 445-8843

(678) 990 5744


Intraday stock chart for alim


Rick Eiswirth

President and Chief Executive Officer

Philip Ashman

COO, Senior VP, Commercial Operations Europe

Dave Holland

CMO, Senior VP Corporate Communications & Managed Markets

Phil Jones

Chief Financial Officer

Samer Kaba M.D

Chief Medical Officer

View Management Team

Past Six Months

6 month stock chart for alim

Recent News & Filings

Alimera Sciences Corporate Presentation 10-K - Dec 31, 2018 10-Q - Mar 31, 2020

Investor Relations

John Marco, CORE IR
377 Oak Street
Garden City, NY 11530
Phone: 516-222-2560

Transfer Agent

AST Financial, Bryan Anderson,
Relationship Manager


Grant Thornton LLP
Joseph Heatherly, Partner,

Corporate Counsel

Charles Vaughn,
Nelson Mullins
(404) 322-6189

Subscribe to IR news and filing alerts

You can opt out at any time. We do not share or sell your info.

Back To Top
Skip to content